AZN.L AZ

AZN.L ASTRAZENECA PLC ORD SHS $0.25

Healthcare · Drug Manufacturers - General

5 · Fair Watch

143.18

+1.82%

About the company

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

1.65% 46.83% 2.36 28.41 5.04 137.39
52w 101.03 157.32

Dividend profile

Frequency Semi-annual Growth (TTM) -3.8% CAGR 3y +3.3% +2.5% 1 year

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Dividend history

14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Debt & leverage

71.81% 0.91 0.70 Total debt 34.0B GBP Total cash 7.7B GBP 20.0B GBP

Latest reported balance-sheet figures.

Held by 1 investor

Sign up for an AI summary of this stock's dividend — and to track it in your portfolio.

Information, not financial advice.

The information on Quantic is provided for informational and educational purposes only. It is general in nature, does not take into account your personal financial situation, and does not constitute investment, financial, tax, or legal advice — nor a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal; past performance is not a reliable indicator of future results. Market data comes from third-party providers and may be delayed or inaccurate. Before making any investment decision, consider your objectives, time horizon, risk tolerance, and diversification, and consult a qualified financial professional. Quantic is not a registered investment adviser or broker-dealer.

Quantic finance

Built with Elixir, Phoenix LiveView, and Tailwind CSS

© 2026 Francesc Leveque · Learn · Frequently Asked Questions